Over the last 12 months, one CytoMed Therapeutics Ltd the people running the company bought into shares with their own money, about $729,000 in total, and none of them sold.
Biggest single buyer: Choo Chee Kong, Director, with roughly $150,000.
Quarter by quarter: 2 quarters in a row of net buying by insiders. Insiders bought in 2 of the last 7 full quarters. Big money check: 3 institutions held GDTC as of Q2 2026, and more funds sold than bought.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | Choo Chee Kong | Director | Buy | 100,000 | $1.50 | $150K | SEC |
| Jul 24, 2026 | Choo Chee Kong | Director | Buy | 100,000 | $1.50 | $150K | SEC |
| Jul 24, 2026 | Choo Chee Kong | Director | Buy | 100,000 | $1.50 | $150K | SEC |
| Jul 24, 2026 | Choo Chee Kong | Director | Buy | 100,000 | $1.50 | $150K | SEC |
| Jun 15, 2026 | Choo Chee Kong | Director | Buy | 112,000 | $1.15 | $129K | SEC |
In the last 12 months CytoMed Therapeutics Ltd insiders made open-market purchases worth about $729,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in GDTC was filed on 2026-07-24.
3 investment managers reported holding GDTC in SEC Form 13F filings for Q2 2026.
No congressional trades in GDTC were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).